The next generation of weight loss medications is coming. Oral pills, triple agonists, and muscle-sparing combinations — here's what's on the horizon.
The GLP-1 market is evolving fast. Here are the drugs that will shape the next 2-3 years — including some that are already available.
The same semaglutide as Wegovy but in pill form. No more injections. FDA approved December 2025, launching January 2026 at $149/month — significantly cheaper than injectable.
Key advantage: No refrigeration needed. Take with water on empty stomach, wait 30 minutes before eating.
Small-molecule oral GLP-1. No food or water restrictions unlike oral semaglutide. NDA submitted December 2025, FDA action date March 2026.
Key advantage: No waiting period after taking. More convenient dosing than oral Wegovy.
Triple agonist (GLP-1 + GIP + glucagon). The most powerful weight loss drug in development. Phase 3 TRIUMPH trials ongoing, projected approval late 2026 or early 2027.
Why it matters: The glucagon component may help preserve muscle while maximizing fat loss.
Combination of semaglutide + cagrilintide (amylin analog). Targets multiple appetite pathways for enhanced weight loss.
Dual GLP-1/glucagon agonist with strong liver benefits. Particularly promising for fatty liver disease (MASH).
Myostatin inhibitor + GLP-1. The BELIEVE trial showed 92.8% of weight loss from fat, preserving muscle. Potential game-changer for body composition.
Current GLP-1 medications are already highly effective. Compare today's options while the pipeline develops.